...the role on an interim basis while the regenerative medicines company searches for a successor.Research firm Evercore ISI... ...company in 2017 as director of operations.
Robin Sawka
Kymera Therapeutics Inc.
Immunovia AB
Apic Bio Inc.
Vor Biopharma Inc.
Organogenesis Inc.
Evercore ISI
Saniona...
...Prevnar 13 or its successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI... ...elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup, UBS, Evercore ISI...
...first nine months of 2019; it does not break out PNH sales for the drugs. Evercore ISI... ...the sale of 7 million shares in a follow-on underwritten by Citigroup, J.P. Morgan and Evercore ISI...
...the role on an interim basis while the regenerative medicines company searches for a successor.Research firm Evercore ISI... ...company in 2017 as director of operations.
Robin Sawka
Kymera Therapeutics Inc.
Immunovia AB
Apic Bio Inc.
Vor Biopharma Inc.
Organogenesis Inc.
Evercore ISI
Saniona...
...Prevnar 13 or its successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI... ...elexacaftor/tezacaftor/ivacaftor. Royalty Pharma's underwriters are J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup, UBS, Evercore ISI...
...first nine months of 2019; it does not break out PNH sales for the drugs. Evercore ISI... ...the sale of 7 million shares in a follow-on underwritten by Citigroup, J.P. Morgan and Evercore ISI...